• Users Online: 106
  • Print this page
  • Email this page
Year : 2021  |  Volume : 20  |  Issue : 2  |  Page : 27-31

Ketamine for treatment-resistant depression

General Psychiatrist in Department of Psychiatry, Almahmodya General Hospital, Baghdad, Iraq

Correspondence Address:
Dr. Raad Saady Madhloom
General Psychiatrist in Department of Psychiatry, Almahmodya General Hospital, Baghdad
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mj.mj_15_21

Rights and Permissions

Major depressive disorder (MDD) is of influence on about 350 million individuals worldwide, which is causing disability consecution and damaging consequences to the affected community and individuals. Treatments as antidepressant are affecting the system of monoamine where symptoms of depressive were relived in about 50% of cases. Such ratio turns into obviously low in depressed persons who failed already to cure following 2 or additional antidepressant drugs at sufficient duration and doses regarding it a treatment-resistant depression (TRD). There is an obvious requisite for quick action and influenced treatments. Ketamine (KMN) is considered an anesthetic old drug that has a promising quick action as an antidepressant in TRD patients with MDD, concentrating on clinical issues, i.e. administration route, dose, and action duration. Other indication proposes that KMN might be influenced in stress disorder as posttraumatic and ideation as acute suicidal.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded138    
    Comments [Add]    

Recommend this journal